替诺福韦酯在慢性乙型肝炎治疗中的进展

Research Progress on Efficacy of TDF in Chronic HBV Infection

慢性乙型肝炎是严重威胁人类健康的疾病,多种核苷(酸)类似物如拉米夫定、阿德福韦酯等长期广泛应用于抗乙型肝炎病毒感染,有效地抑制病毒复制,但随着应用时间延长,其较高的耐药率也受到了广泛的关注。替诺福韦酯2008年被批准用于慢性乙型肝炎的抗病毒治疗,并显示了良好的疗效。多项研究证实,替诺福韦酯在拉米夫定耐药者及阿德福韦酯耐药者均发挥了良好的抗病毒作用。

Chronic hepatitis B is a serious threat to human health.A variety of nucleotide and nucleoside analogues such as lamivudine and adefovir are widely applied in the management of hepatitis B virus infection,but the high resistant rate earns more attentions as the application time prolonged. Tenofovir was approved for antiviral treatment for chronic hepatitis B in 2008 and showed good curative effect.A number of studies have confirmed that tenofovir could also play a good role in the patients with lamivudine or adefovir resistance.